Professional Documents
Culture Documents
by
Prof. K. K. Jain
MD, FRACS, FFPM
Jain PharmaBiotech
Basel, Switzerland
July 2012
AUTHOR'S
BIOGRAPHY
July 2012
Copyright 2012 by
Jain PharmaBiotech
Blsiring 7
CH-4057 Basel
Switzerland
Tel & Fax:
Email:
Web site:
+4161-6924461
info@pharmabiotech.ch
http://pharmabiotech.ch/
All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted
in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written
permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the
consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information
presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.
-2-
TABLE
OF
CONTENTS
-3-
-4-
-5-
-6-
-7-
-8-
-9-
- 10 -
- 11 -
- 12 -
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Figures
Figure 1-1: Percentages of world population of people over the age of 65 according to more
developed and less developed portions 2000 to 2050. ......................................................... 32
Figure 1-2: Correlation between aging and AD in the US from 2000 to 2020 ..................................... 33
Figure 1-3: Prevalence of different types of dementia ..................................................................... 34
Figure 1-4: Mechanisms of A clearance ....................................................................................... 46
Figure 1-5: Nitric oxide neurotoxicity and neuroprotection in relation to Alzheimer disease ................. 62
Figure 1-6: Oxidative stress and Alzheimer disease ........................................................................ 64
Figure 1-7: Role of proteosome inhibition in A generation and neurodegeneration ............................ 69
Figure 1-8: Pathomechanism of AD .............................................................................................. 81
Figure 3-1: Metabolism of acetylcholine ...................................................................................... 147
Figure 3-2: Neuroprotective effective of galantamine in AD ........................................................... 151
Figure 3-3: Strategies for the management of Alzheimer disease ................................................... 179
Figure 5-1: NMDA receptor ion channel complex. ......................................................................... 208
Figure 5-2: Neurotoxicity due to misfolding of A1-42 .................................................................. 243
Figure 5-3: Role of proteomics in drug discovery/development for Alzheimer disease ....................... 308
Figure 6-1: Unmet needs in the management of Alzheimer disease ................................................ 335
- 13 -